Alector‘s patent involves using anti-Siglec-5 antibodies to prevent or treat diseases like Alzheimer’s and cancer by targeting Siglec-5 proteins. The method includes administering specific antibody compositions to individuals in need, inhibiting interactions between Siglec-5 and its ligands. GlobalData’s report on Alector gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Alector Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Alector, Personalized cancer vaccines was a key innovation area identified from patents. Alector's grant share as of April 2024 was 18%. Grant share is based on the ratio of number of grants to total number of patents.

Anti-siglec-5 antibody for treating alzheimer's disease and cancer

Source: United States Patent and Trademark Office (USPTO). Credit: Alector Inc

A recently granted patent (Publication Number: US11965023B2) outlines a method for preventing, reducing the risk of, or treating diseases such as Alzheimer's disease and cancer by administering an anti-Siglec-5 antibody. This antibody is designed to decrease cellular levels of Siglec-5, inhibit interactions between Siglec-5 and its ligands, or both. The patent specifies the amino acid sequences of the antibody's light and heavy chain variable regions, emphasizing its potential therapeutic efficacy in cancers expressing Siglec-5 or its ligands.

Furthermore, the patent details how the anti-Siglec-5 antibody can impact various activities associated with cancer progression, including promoting the proliferation of immunosuppressive cells, enhancing tumor infiltration, and modulating the tumor microenvironment to favor tumor growth. The method also involves administering additional antibodies targeting inhibitory checkpoint molecules or cytokines, as well as standard or investigational anti-cancer therapies. By combining these treatments, the patent aims to enhance the efficacy of cancer therapies and potentially improve patient outcomes across a range of cancer types, including bladder, brain, breast, and lung cancer, among others. The specificity of the antibody to Siglec-5 and its potential to modulate immune responses and tumor growth highlight its significance in the development of novel therapeutic strategies for cancer treatment.

To know more about GlobalData’s detailed insights on Alector, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies